SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Pictured: Patient taking pills at hospital/iStock:
Less Than Half of New Drug Approvals Add Therapeutic Value Over Existing Treatments: Study
The proportion of supplemental indications rated as having high therapeutic value was substantially lower than for first indications, according to a new study published Wednesday in The BMJ.
July 6, 2023
 · 
2 min read
 · 
Kate Goodwin
AstraZeneca's sign on its office in California
Drug Development
AstraZeneca’s Phase III Lung Cancer Data Underwhelms Investors
Topline results for its Daiichi Sankyo-partnered antibody-drug conjugate showed statistically significant improvement. However, AstraZeneca shares dropped around 6% in early Monday trading.
July 3, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Physician shows shape of liver/iStock, S
Drug Development
Ipsen, Genfit Tout Phase III Data for Liver Disease Drug, Seek FDA and EMA Approvals
The companies Friday reported positive late-stage results for elafibranor as a second-line treatment for primary biliary cholangitis, a rare liver disease.
June 30, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Eli Lilly's biotechnology center in San Diego, California
Deals
Lilly to Buy Diabetes Cell Therapy Partner Sigilon for Just Over $300M
Eli Lilly announced Thursday it will acquire former collaborative partner Sigilon Therapeutics to deepen its diabetic foothold with a potentially functional cure for Type 1.
June 29, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Analyst pointing to stock chart / iStock
Drug Development
MoonLake Looks to Raise $250M in Stock Offering on Heels of Mid-Stage Data
Phase II results of MoonLake’s sonelokimab suggest superiority to the competition. Funds raised in the stock offering will support Phase III trials with an anticipated launch in 2027.
June 27, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: FibroGen sign/Smith Collection/Gado/Gett
Drug Development
Second Strike for FibroGen’s Pamrevlumab—First Duchenne, Now Lung Fibrosis
FibroGen takes another hit as its antibody hopeful fails in a second indication. The biopharma says that it is cutting costs to extend its cash runway.
June 26, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: 3D illustration of antibody-drug conjugates with their toxic payloads
Novartis-Backed Tagworks Raises $65M Series A to Further ADC, Click-to-Release Tech
The biotech is leveraging the potential of antibody-drug conjugates for non-internalizing targets in solid tumors through its proprietary Click-to-Release platform.
June 22, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: Vyvgart Hytrulo Bottle/argenx
FDA
FDA Approves First Subcutaneous Injectable for Muscle-Weakening Disease
Argenx’s Vyvgart will now be available in the U.S. as a more convenient subcutaneous formulation 18 months after its first approval.
June 21, 2023
 · 
2 min read
 · 
Kate Goodwin
FDA sign outside its office in Maryland
Drug Development
FDA Lifts Partial Hold on Arcellx’s Multiple Myeloma Trial After Patient Death
The study participant who died was apparently ineligible for the treatment according to the trial protocol, Arcellx announced Monday. The company has since retrained the study’s clinical sites.
June 20, 2023
 · 
3 min read
 · 
Kate Goodwin
Pictured: T cells attacking and killing cancer cel
FDA
Roche, AbbVie to Compete for Lymphoma Market Share with New BsAbs
With Roche’s FDA approval on Thursday, both companies’ bispecific antibodies will hit the market this summer for relapsed or refractory diffuse large B-cell lymphoma.
June 16, 2023
 · 
3 min read
 · 
Kate Goodwin
Pictured: DNA strand on background of binary code/
Child Dies, Two in Remission After Treatment with First Base-Edited Cell Therapy
Two children with relapsed T cell acute lymphoblastic leukemia were cleared of cancer while a third died from fungal infection, according to research published Wednesday in The New England Journal of Medicine.
June 15, 2023
 · 
3 min read
 · 
Kate Goodwin
Pictured: T cells attacking cancer/ iStock, Design
Drug Development
FDA Puts 2seventy bio’s CAR-T Trial on Formal Hold After Patient Death
The company announced Monday with its second-quarter earnings that the regulator has officially halted the Phase I study after a child with acute myeloid leukemia died following treatment.
June 14, 2023
 · 
3 min read
 · 
Kate Goodwin
Pictured: Illustration of a lymphoma cell/iStock,
Drug Development
Seagen Touts Adcetris Early-Stage Lymphoma Data with 93% Complete Remission
Data from a Phase II trial showed that Adcetris, used in a combination approach, is effective in early-stage classical Hodgkin lymphoma patients.
June 13, 2023
 · 
2 min read
 · 
Kate Goodwin
Jonathan Weiss/Shutterstock
Business
AstraZeneca, Quell Team to Develop Cell Therapies in Potential $2B Deal
The company paid $85 million upfront to Quell Therapeutics to develop Treg therapies for Type 1 diabetes and inflammatory bowel disorder, with the deal potentially worth more than $2 billion.
June 9, 2023
 · 
2 min read
 · 
Kate Goodwin
Pictured: FibroGen sign/Smith Collection/Gado/Gett
Drug Development
FibroGen’s Duchenne Muscular Dystrophy Drug Fails Phase III Trial
In a late-stage study of non-ambulatory patients with DMD on background corticosteroids, pamrevlumab failed to meet the primary endpoint for upper limb performance.
June 7, 2023
 · 
2 min read
 · 
Kate Goodwin
Load More